Virios Therapeutics Soars Over 33 percent on Merger Announcement
| SPRC Stock | USD 0.31 0.02 6.90% |
About 55% of Scisparc's shareholders are presently thinking to get in. The analysis of overall sentiment of trading Scisparc stock suggests that some investors are interested at this time. The current market sentiment, together with Scisparc's historical and current headlines, can help investors time the market. In addition, many technical investors use Scisparc stock news signals to limit their universe of possible portfolio assets.
Virios Therapeutics experienced a pre-market surge of over 33, with shares trading at 0.183. The company announced a definitive share exchange agreemen
Read at gurufocus.com
 |
Scisparc Fundamental Analysis
We analyze Scisparc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scisparc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scisparc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Working Capital
Working Capital Comparative Analysis
Scisparc is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
Scisparc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scisparc stock to make a market-neutral strategy. Peer analysis of Scisparc could also be used in its relative valuation, which is a method of valuing Scisparc by comparing valuation metrics with similar companies.
Peers
Scisparc Related Equities
| TIL | Instil Bio | 51.73 | ||||
| NUVB | Nuvation Bio | 10.84 | ||||
| QNRX | Quoin Pharmaceuticals | 6.01 | ||||
| CTMX | CytomX Therapeutics | 4.41 | ||||
| REVB | Revelation Biosciences | 0.78 | ||||
| ASMB | Assembly Biosciences | 0.22 | ||||
| HOTH | Hoth Therapeutics | 1.18 | ||||
| KPRX | Kiora Pharmaceuticals | 1.29 | ||||
| ZVSA | ZyVersa Therapeutics | 1.82 | ||||
| CDIO | Cardio Diagnostics | 2.08 | ||||
| UNCY | Unicycive Therapeutics | 3.51 | ||||
| VRAX | Virax Biolabs | 3.85 | ||||
| CVKD | Cadrenal Therapeutics, | 4.27 |
Complementary Tools for Scisparc Stock analysis
When running Scisparc's price analysis, check to measure Scisparc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scisparc is operating at the current time. Most of Scisparc's value examination focuses on studying past and present price action to predict the probability of Scisparc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scisparc's price. Additionally, you may evaluate how the addition of Scisparc to your portfolios can decrease your overall portfolio volatility.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals |